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Tolerance to specific antigens is the ultimate 
therapeutic goal in two major immunological 
fields, autoimmunity and transplantation rejec-
tion. Over the past several decades, the genera-
tion of a large array of immunosuppressive agents 
has increased the number of therapeutic tools 
available to address these two issues. The focus 
has now shifted to tackling the side effects of 
long-term immunosuppression. The final goal 
is to achieve T and B cell tolerance that is anti-
gen specific without the need for long-term 
generalized immunosuppression.
The  mechanisms  that  underlie  peripheral   
T cell tolerance have been explained, in part, al-
though some points remain to be addressed. DCs 
have a key role in immune regulation (Steinman 
et al., 2003). Antigen presentation by immature 
and semimature DCs results in immune tolerance 
rather than effective T cell immunity because of 
the  failure  to  provide  sufficient  co-stimulatory 
signals (Reis e Sousa, 2006; Morelli and Thomson, 
2007; Shortman and Naik, 2007). These tolero-
genic  DCs  are  characterized  by  low-level   
expression of surface MHC molecules and sev-
eral other co-stimulatory receptors and the pro-
duction of low levels of Th1 cytokines, notably   
IL-12p70 (Morelli and Thomson, 2007).
Among several mouse anti–human ICAM-1   
(intercellular adhesion molecule 1) antibody 
clones we have developed thus far, we were 
able to select only one clone, MD-3, which 
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Induction of antigen-specific T cell tolerance would aid treatment of diverse immunological 
disorders and help prevent allograft rejection and graft versus host disease. In this study, we 
establish a method of inducing antigen-specific T cell tolerance in situ in diabetic humanized 
mice and Rhesus monkeys receiving porcine islet xenografts. Antigen-specific T cell tolerance 
is induced by administration of an antibody ligating a particular epitope on ICAM-1 (inter-
cellular adhesion molecule 1). Antibody-mediated ligation of ICAM-1 on dendritic cells (DCs) 
led to the arrest of DCs in a semimature stage in vitro and in vivo. Ablation of DCs from mice 
completely abrogated anti–ICAM-1–induced antigen-specific T cell tolerance. T cell responses 
to unrelated antigens remained unaffected. In situ induction of DC-mediated T cell tolerance 
using this method may represent a potent therapeutic tool for preventing graft rejection.
© 2011 Jung et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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in the periphery (Hiramatsu et al., 2003; Traggiai 
et al., 2004). Current humanized mouse models 
have some minor defects, particularly in innate 
immunity, such as incomplete reconstitution of 
NK cells and poor development of myeloid lin-
eage cells (Chen et al., 2009). However, unlike 
the hu-PBL-SCID mouse, which lacks normal 
lymphoid organs and architecture (Tary-Lehmann et al., 1995), 
the immune cells in the spleens of NOG mice reconstituted 
with human HSCs showed a fairly good organization into 
white and red pulp (Strowig et al., 2009). In particular, the 
model allows effective reconstitution of T and B cells. More-
over, T cells in these humanized mice were able to control in-
fection with Epstein-Barr virus (Strowig et al., 2009). In this 
respect, a humanized mouse can be considered to be the most 
appropriate animal model for the assessment of the human   
immune system (Shultz et al., 2007).
We previously provided theoretical evidence for the gen-
eration of a unique population of CD4+ T cells, so-called T-T 
CD4+ T cells, that are restricted by human MHC class II mol-
ecules on thymocytes rather than by those on mouse thymic epi-
thelial cells in humanized mice (Choi et al., 1997, 2005; Lee 
et al., 2010). These T cells have a diverse TCR repertoire (Choi 
et al., 2005; Li et al., 2005). Moreover, a recent study from 
our  laboratory  demonstrated  that  T-T  CD4+  
T cells do exist in humans (Lee et al., 2010; Min 
et al., 2011). Most recently, PLZF (promyelocytic 
was cross-functional with ICAM-1 molecules on nonhuman 
primates. Epitope-based ligation of ICAM-1 on immature 
DCs with this antibody led to the arrest of DCs in a semi-
mature  stage.  They  expressed  low  levels  of  MHC  and   
co-stimulatory molecules on their surfaces and displayed sig-
nificantly lower production of inflammatory cytokines.
The generation of humanized mice through the engraft-
ment of human hematopoietic stem cells (HSCs) provides a 
powerful tool for investigating various human biological pro-
cesses, notably in vivo immune responses, the study of which 
would otherwise not be possible (Ito et al., 2002; Manz, 2007; 
Shultz  et  al.,  2007;  Brehm  et  al.,  2010;  Issa  et  al.,  2010).   
Engraftment of human HSCs in NOD.SCID/c/ (NOG) 
mice is more efficient than other previously described human-
ized mouse models (Ito et al., 2002; Brehm et al., 2010). These 
mice exhibit long-term engraftment of HSCs in the recipient 
bone marrow and generation of all human blood lineage cells 
Figure 1.  Development of an anti–human ICAM-1 
antibody. (A) HEK293 cells were transfected with vector 
alone or vector encoding domains 1, 2, or 3–5 of human (h) 
or mouse (m) ICAM-1. MD-3 binding was assessed by flow 
cytometry. (B) PBMCs or neutrophils were incubated with 
human umbilical vein endothelial monolayers in the absence 
(negative control [NC]) or presence of monoclonal antibodies 
specific for CD18 (IB4) or ICAM-1 (R6.5) with MD-3, all at  
20 µg/ml. Adhesion was measured as described in Materials 
and methods. Data are expressed as the mean adhesion 
relative to control ± SE of three experiments (except IB4 in 
the monocyte adhesion assay, where n = 2), with six replicates 
per experiment. n.s., not significant; *, P < 0.05; ***, P < 0.001.
Figure 2.  Human hematopoietic cell engraftment 
and immune cell development in humanized mice.  
(A) Data represent the percentage of human HLA-ABC+ 
or CD3+ cells in the peripheral blood of consecutively 
analyzed mice at the indicated weeks after transplanta-
tion of human CD34+ cells. Cumulative data (n = 111) 
were obtained from >10 independent experiments. Hori-
zontal bars indicate the mean. (B) Flow cytometry data 
show CD4+CD3+ or CD8+CD3+ T cells, B cells (CD19+), 
monocytes (CD14+), and conventional (CD11c+) or plas-
macytoid (CD123+) DCs in the spleen. Data shown are 
representative of more than five independent experi-
ments. (C) Flow cytometry data show the individual pop-
ulation of CD14+CD15 monocytes and CD14CD15+ 
neutrophils in the peripheral blood. Shown are represen-
tative data from one experiment of two mice.JEM Vol. 208, No. 12 
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cells.  Individual  transfectants  were  analyzed  to  identify   
the  MD-3  antibody–binding  site  in  the  extracellular   
domain of the ICAM-1 molecule. The results of flow cyto-
metric analysis showed that MD-3 bound to domain 2 of 
ICAM-1 (Fig. 1 A).
ICAM-1 mediates leukocyte–leukocyte and leukocyte–
endothelial interactions by binding to LFA-1 (lymphocyte 
function–associated  antigen  1)  and  Mac-1  (Dustin  et  al., 
1986). Thus, some antibodies directed against ICAM-1 or 
LFA-1 could block leukocyte adhesion to endothelial cells 
(Smith et al., 1988) and T cell activation (Sanchez-Madrid   
et al., 1982), resulting in prolongation of allograft survival 
(Badell et al., 2010). Particularly, some antibodies against do-
main 2 of ICAM-1 such as R6-5-D6 could inhibit LFA-1 
adhesion,  although  the  LFA-1–binding  site  is  located  in   
domain 1 of ICAM-1 (Berendt et al., 1992). Therefore, we inves-
tigated whether the adhesion of leukocytes to human umbilical 
vein endothelial cells (HUVECs) was affected by MD-3 
leukemia zinc finger)-negative T-T CD4+ T cells were shown 
to be similar to conventional naive T cells with respect to a 
lack of expression of activation/memory markers and to be 
functionally equivalent to conventional naive CD4+ T cells in 
terms of B cell help (Kim et al., 2011). Therefore, humanized 
mice can be considered to be representative models that mimic 
the human immune system (Issa et al., 2010). In this study, we 
successfully  established  in  situ  induction  of  antigen-specific   
T cell tolerance both in humanized mice and nonhuman 
primates  and  examined  cellular  mechanisms  with  which   
DC-based T cell tolerance is achieved.
RESULTS
Development of an immune-modulating anti–human  
ICAM-1 antibody
To localize the MD-3–binding site in ICAM-1, a series of 
domain-based fusion constructs with human and mouse 
ICAM-1 genes were generated and then expressed in HEK293 
Figure 3.  Assessment of graft survival in humanized mice. Porcine islets were transplanted under the renal capsule of humanized mice that had 
been rendered diabetic by STZ or were nondiabetic and received an injection of isotype-matched irrelevant control or MD-3 antibody (Ab). (A) Experi-
mental protocol. (B) Fasting blood glucose (open circles; right y axis) and porcine C-peptide (closed squares; left y axis) levels were monitored weekly.  
(C) Based on serum level of porcine C-peptide, functional survival of islet xenografts was plotted over time. The dotted line indicates the day when a portion 
of the mice were sacrificed for ELISPOT and histopathological analyses. (D) Serial kidney sections of a representative mouse in the control or MD-3–
treated groups were stained with H&E or antibodies specific for insulin, human CD3, or human CD68. Bar, 100 µm.2480 Inducing T cell tolerance in situ | Jung et al.
infiltrates, in which CD3+ T cells and either CD68+ macro-
phages were the predominant cellular components (Fig. 3 D, 
top). In contrast, in the MD-3–treated group, large nests of 
insulin-positive porcine islet cells were clearly seen in the sub-
capsular  area  of  the  kidney  with  negligible  infiltration  of 
mononuclear cells in the peri-islet area (Fig. 3 D, bottom).
Although MD-3 treatment resulted in the prolonged sur-
vival of xenografts in humanized mice, it was unclear whether 
the lack of an immune response was a result of antigen-specific 
or generalized immunosuppression. To address this, we se-
lected two third-party stimulating antigens: a cellular allo-
antigen and soluble KLH. When total splenocytes from control 
mice were stimulated with porcine islets, significant numbers 
of IL-2– and IFN-–secreting T cells were detected (Fig. 4, 
A and B, left). In contrast, IL-2– and IFN-–secreting T cells 
were almost completely absent from MD-3–treated mice, indi-
cating the complete suppression of T cell responses to xeno-
antigens. In this system, the activation of T cells in response 
to human alloantigens, as assessed by mixed lymphocyte reac-
tion (MLR), was comparable with that of controls (Fig. 4,   
A and B, middle). These data suggest that the unresponsive-
ness of the T cells does not reflect generalized immuno-
suppression, but rather the induction of T cell tolerance specific 
for porcine islet antigens. This induction of antigen-specific 
T cell tolerance was further indicated by in vivo challenge 
with  an  unrelated  soluble  antigen,  KLH.  At  day  28  after 
transplantation, at which time MD-3 had been cleared com-
pletely, mice were immunized with soluble KLH antigen.   
2 wk later, splenocytes were isolated and restimulated with 
the same antigen in an ex vivo system, 
and  the  numbers  of  KLH-specific   
T cells were evaluated in an ELISPOT 
assay. As shown in Fig. 4 (A and B, 
right), there was a clear anti-KLH re-
sponse in MD-3–treated mice in terms 
(Fig. 1 B). Unlike anti-CD18 antibody (IB4) and R6-5-D6, 
which inhibited the adhesion of peripheral blood leukocytes 
to HUVECs, MD-3 did not affect these adhesions.
In situ induction of antigen-specific T cell tolerance  
by MD-3 treatment in humanized mice
To investigate the induction of T cell tolerance, we estab-
lished a porcine islet xenograft model in humanized mice, 
which were properly repopulated with human immune cells 
(Fig. 2). In these mice, T and B cells were fully repopulated 
14–16 wk after i.v. injection of human cord blood CD34+ 
cells (Fig. 2 B). Diabetes was induced through two injections 
of streptozotocin (STZ; total dose, 200 mg/kg) before trans-
plantation. Control animals received an irrelevant IgG1 mono-
clonal antibody, and the experimental group received MD-3. 
These two antibodies were injected into mice three times   
at 3-d intervals (dose 300 µg per mouse) before islet trans-
plantation (Fig. 3, A and B [top]). Humanized mice that did 
not receive STZ before porcine islet transplantation were also 
examined to exclude any possible effect of STZ on MD-3 
antibody function and generalized immune response (Fig. 3 B, 
bottom). Blood glucose and serum porcine C-peptide levels 
were monitored weekly (Fig. 3 B), and mice were sacrificed 
42 d after the initial transplantation (Fig. 3 C).
Median graft survival in the control group was 24.5 d. In 
contrast, animals treated with MD-3 showed no evidence of 
graft rejection up to the time of their sacrifice at 42 d (Fig. 3, 
B and C). In the control group, insulin-positive porcine islet 
cells were completely destroyed and replaced by inflammatory 
Figure 4.  Induction of antigen-specific  
T cell tolerance in humanized mice. To assess 
antigen-specific T tolerance in humanized 
mice that received the islet graft, some recipi-
ent mice were challenged with KLH at 4 wk 
after transplant. Splenocytes were isolated at 
6 wk after transplant and tested for recall IL-2 
and IFN- responses against donor islets, 
human allogeneic blood mononuclear cells 
(MLR), and KLH by ELISPOT assay. (A) Repre-
sentative results. (B) Summarized data from 
4–11 mice are presented as total numbers of 
cytokine-producing cells per 3 × 105 spleno-
cytes. As a negative control (NC) for anti-islet 
response, splenocytes from humanized mice 
that did not undergo transplantation (un-
grafted) were stimulated with porcine islets. 
In contrast, splenocytes from engrafted mice 
cultured in the absence of stimulating antigen 
(responder only) were used as a negative con-
trol for MLR and anti-KLH responses. Horizon-
tal bars represent mean values. Ab, antibody.JEM Vol. 208, No. 12 
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lower in MD-3–treated cells than in those treated with the 
control antibody (Fig. 5 B). The phenotype and function of DCs 
treated with MD-3 during their maturation were consistent 
with the features of semimature or tolerogenic DCs (Morelli and 
Thomson, 2007). Thus, these in vitro results suggest that MD-3 
alone can arrest DC maturation in a semimature state.
Next, to analyze the effect of MD-3 on DC maturation 
status in vivo, we injected MD-3 and control antibodies into 
humanized mice three times at 3-d intervals and then treated 
them with LPS. At 24 h after LPS treatment, DCs in spleens 
were analyzed for surface expression of CD80 and CD86 
(Fig. 5 C, left and middle), and their numbers in control and 
MD-3–treated groups were compared (Fig. 5 C, right). As 
anticipated, the expression of both surface molecules was re-
duced in DCs from MD-3–treated mice versus the control 
group (Fig. 5 C). These in vivo results, together with the 
aforementioned in vitro data, suggest that this form of matu-
ration arrest could be achieved through in vivo treatment 
with MD-3 alone.
Because  ICAM-1  is  expressed  on  vascular  endothelial 
cells, as well as activated T and B cells, we next determined 
(a) whether there are any changes in the surface expression of 
MHC  and  co-stimulatory  molecules  and  the  production   
of inflammatory cytokines in HUVECs and activated T cells 
and  (b)  antibody  production  in  activated  B  cells,  when 
treated  with  MD-3  antibody.  In  HUVECs,  we 
were not able to see any differences in surface ex-
pression and cytokine production of control and 
of the numbers of cells producing IFN- and IL-2. These data 
again suggest that a normal immune response to KLH oc-
curred in humanized mice that had been tolerized against di-
verse antigens from grafted porcine islets, indicating that the 
response was antigen specific.
MD-3 treatment arrests human DCs in a semimature stage 
in vitro and in vivo
We next investigated whether MD-3 could modulate the 
maturation status of human monocyte-derived DCs. Human 
CD14+  monocytes,  isolated  as  precursors  of  monocyte- 
derived DCs, were incubated for 6 d with GM-CSF and   
IL-4, in the presence of MD-3 or a control antibody, to induce 
their differentiation into immature DCs. Subsequently, im-
mature DCs were treated with the Toll-like receptor agonist, 
LPS (maturation signal), for 1 d and then analyzed for cyto-
kine production and surface expression of molecules linked 
to antigen presentation. As shown in Fig. 5 (A and B), treat-
ment of monocytes with MD-3 from the beginning of culture 
resulted in the arrest of DC maturation in a semimature state. 
This differentiation state was confirmed by the expression of 
surface molecules, such as MHC classes I & II, CD80, CD86, 
and CD40, at levels between those of immature and mature 
DCs (Fig. 5 A). Furthermore, the production of cytokines, 
notably IL-12p70, IFN-, IL-6, and TNF, was significantly 
Figure 5.  Arrest of DC maturation at the semimature 
stage. Immature monocyte-derived DCs were generated 
from human CD14+ monocytes by incubation with GM-CSF 
and IL-4 in the presence of MD-3 or isotype-matched con-
trol antibody (control Ab) from the beginning of culture. 
After 6 d, DCs were stimulated or not with LPS. (A) Expres-
sion levels of MHC class I and II, CD80, CD86, CD40, PD-L1, 
PD-L2, and CTLA-4 on their surface were compared by flow 
cytometry. Cumulative data showing mean fluorescent in-
tensity (MFI) ± SE of MHC class I and II, CD80, CD86, and 
CD40 were obtained from four independent experiments. 
Data showing mean fluorescent intensity ± SE of PD-L1,  
PD-L2, and CTLA-4 are representative of two independent 
experiments in triplicate. (B) Representative cytokine levels in 
the culture supernatants of immature and LPS-treated 
monocyte-derived DCs in the presence of MD-3 or control 
antibody. Results are the mean ± SE of triplicate cultures, 
and data are representative of three independent experi-
ments. (C) Humanized mice received MD-3 or control anti-
body three times before LPS (100 µg/mouse) administration. 
Splenocytes were isolated 1 d after LPS injection and stained 
with HLA-ABC, CD11c, CD80, and CD86 antibodies. Repre-
sentative dot plots of CD80 and CD86 expression on gated 
CD11c+ DCs are shown at the left. Numbers indicate the 
percentage of cells in each quadrant. Cumulative data (n = 3)  
showing mean fluorescent intensity were obtained from 
three independent experiments (middle). The percentages of 
CD11c+ cells among HLA-ABC+ cells in spleens were also 
calculated (right). Error bars indicate SE.2482 Inducing T cell tolerance in situ | Jung et al.
whereas mice treated with MD-3 alone mounted a T cell 
tolerance to xenoantigen challenge (Fig. 6 C, left).
Next, we examined whether the T cell response that had 
returned against islet antigens was caused by the recovery of 
a normal immune response, which had been lost via the   
ablation of DCs. To that end, we assessed T cell responses to 
KLH in both mouse groups. Both groups exhibited clear   
T cell responses to KLH (Fig. 6 C, middle). However, in 
these experiments, numbers of KLH-responding T cells were 
reduced in anti-CD11c IT–treated mice, probably because of 
actual  decreases  in  the  numbers  of  DCs  present  in  their 
spleens (Fig. 6 D), suggesting that there may still have been a 
low level of toxicity. To normalize the anti-islet immune re-
sponse based on the individual immune status of the mouse, 
we divided the number of islet-responding T cells by the 
number of spots responding to KLH stimuli in each mouse 
and expressed the relative value as a percentage. The data ob-
tained demonstrated a clear difference in the T cell response 
to islet antigens between the two groups (Fig. 6 C, right). 
These results indicate that the induction of antigen-specific   
T cell tolerance depends primarily on DCs.
MD-3 efficiently induces antigen-specific T cell  
tolerance in nonhuman primates
Although humanized mice are powerful tools for exploring 
the functions of T and B cells and DCs, there are certain 
limitations when extrapolating humanized mouse data to 
humans. This includes the lack of granulocytic   
series, NK cells, and other as of yet unidentified 
factors (Shultz et al., 2007). Fortunately, similar to 
the  human  system,  MD-3  antibody  binds  to   
domain 2 of Rhesus ICAM-1 (Fig. 7 A). There-
fore, to test whether data from the humanized mouse 
system could be reproduced in a nonhuman primate 
model, we conducted the same analyses in Rhe-
sus macaques.
MD-3–treated groups (not depicted). This was also the case 
in activated T cells in terms of T cell proliferation and   
cytokine  production  (not  depicted).  Finally,  LPS-treated   
B cells did not show any differences in total Ig secretion 
(not depicted).
DCs play a major role in MD-3–induced antigen-specific  
T cell tolerance
To confirm that DCs play a key role in the induction of anti-
gen-specific  tolerance  in  vivo,  we  established  a  modified 
mouse model system in which DCs were almost completely 
depleted by the systemic administration of saporin-conjugated 
anti-CD11c immunotoxin (IT; Fig. 6 A). Before porcine   
islet transplantation, MD-3 was administered three times to 
humanized mice in two different groups, one of which re-
ceived anti-CD11c IT at 2-d intervals (Fig. 6 A). As shown 
in Fig. 6 B, intraperitoneal injection of anti-CD11c IT nearly 
completely ablated DCs in humanized mice up to 10 d after 
islet graft. Serum MD-3 levels were measured two times per 
week, and MD-3 was not detected at 7 d after transplanta-
tion. At 12 d after transplantation, both groups of humanized 
mice were immunized with a mixture of alum and KLH. 
Importantly, 26 d after transplantation, numbers of IL-2– and 
IFN-–secreting T cells after rechallenge of porcine islet cells ex 
vivo differed significantly between control and DC-ablated 
mice. Ablation of CD11c+ DCs at the time of xenoantigen 
challenge resulted in severe impairment of T cell tolerance, 
Figure 6.  Abrogation of T cell tolerance induction 
after DC ablation. Humanized mice received anti-CD11c IT 
(-CD11c; 5 µg/mouse) or PBS every other day from 3 d 
before porcine islet transplantation up to the fifth day after 
transplant (D+5). These mice were then immunized with KLH 
on the 12th day after transplant (D+12). (A) Experimental 
scheme. (B) Flow cytometric analysis on the indicated days 
after islet transplantation to assess depletion of CD11c+ DCs 
in the spleen of humanized mice. (C) Splenocytes were iso-
lated 14 d after KLH immunization and tested for recall IL-2 
and IFN- responses via ELISPOT assay against donor islets 
and KLH. The data from individual mice are presented as 
total numbers of cytokine producing cells per 3 × 105 sple-
nocytes or normalized anti-islet response (Islet/KLH) by di-
viding the anti-islet spot number by the anti-KLH spot 
number in each mouse. Horizontal bars represent mean val-
ues. (D) Splenocytes from each mouse were stained with 
anti–human CD11c and anti–HLA-ABC antibodies, and the 
total number of CD11c+ DCs was calculated after flow cyto-
metric analysis. Error bars indicate SE.JEM Vol. 208, No. 12 
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DISCUSSION
For more than the past two decades, various monoclonal anti-
bodies that block interactions between co-stimulatory mole-
cules and their ligands on T cells have been developed to 
control unwanted immunological reactions (Ford and Larsen, 
2009). However, a major problem of using these tools is   
that they cause generalized immunosuppression rather than   
antigen-specific T cell tolerance. In this study, we success-
fully established in situ induction of antigen-specific T cell 
tolerance and dissected the cellular mechanisms underlying 
these findings.
MD-3 binds to the second domain of human ICAM-1. 
When Toll-like receptors on DCs bind LPS in the presence 
of MD-3, the DCs are not fully mature and express cell sur-
face molecules linked to antigen presentation at levels inter-
mediate between those in immature and fully mature DCs. 
Importantly, the cytokine profiles of control and MD-3–
treated  groups  showed  even  greater  differences  (>100- 
fold). A few previous studies have shown that stable T cell 
contacts are required for full activation, whereas repeated 
brief DC–T cell interactions are characteristic of induction of 
T cell tolerance (Hugues et al., 2004; Shakhar et al., 2005). 
Based on these findings, MD-3–mediated induction of semi-
mature DCs seems to result in both a short duration of DC– 
T cell interaction and a shortage of cytokines, and thereby 
induction of T cell tolerance. The possibility that tolerance 
induction was caused by a defect in transendothelial migra-
tion can be ruled out by the findings of a cell adhesion assay, 
which revealed no difference in adhesion activity between 
Rhesus macaques, in which diabetes had been induced 
through the injection of STZ, underwent i.v. glucose toler-
ance testing to confirm the absence of insulin and C-peptide 
production before porcine islet cell transplantation. Recipi-
ent monkeys (R043, R042, and R038) were treated with 
MD-3 alone before intraportal injection of porcine islets 
(50,000  islet  equivalents  [IEQs]/kg).  MD-3  monotherapy 
failed to achieve graft survival for >8 d, whereas ELISPOT 
analysis of PBMCs isolated from three recipient monkeys   
revealed  near-complete  suppression  of  IFN-  and  IL-2   
responses to donor pig islet antigen from day 7–47 (Fig. 7 B), 
clearly indicating the induction of T cell tolerance to por-
cine  islets.  However,  long-term  graft  survival  was  finally 
achieved with a combination treatment of low-dose rapa-
mycin (trough level 6–12 µg/ml) and chimeric anti-CD154 
blocking antibody (5C8; National Institutes of Health), as 
well as MD-3. This combined therapy of rapamycin and chi-
meric ant-CD154 antibody were known to regulate NK and 
NK-mediated innate B cell activation, which has been reported 
to be related to T-independent antigens, such as galactose- 
-1,3-galactose (Gal) and non-Gal sugar antigens (Li et al., 
2007; Eissens et al., 2010). This protocol prolonged the graft 
survival to >140 d as indicated by a normal blood glucose 
level and sustained high level of porcine C-peptide (Fig. 8 A). 
Importantly, these two monkeys (R052 and R049) again 
maintained xenoantigen-specific T cell tolerance as shown 
by suppression of IFN- and IL-2 responses to donor pig 
islet antigens, whereas an intact immune response to a third 
party of alloantigen was maintained (Fig. 8 B).
Figure 7.  Induction of T cell tolerance 
in a nonhuman primate. (A) HEK293 cells 
were transfected with Rhesus ICAM1 gene or 
chimeric genes of Rhesus and mouse ICAM-1, 
and MD-3 binding was assessed by flow 
cytometry (solid line). As the negative con-
trol (dotted line), the cells were stained with 
only FITC-conjugated secondary antibody.  
(B) Adult porcine islets (50,000 IEQs/kg) were 
intraportally transplanted into three Rhesus 
monkeys (R043, R042, and R038) that re-
ceived MD-3 antibody alone. PBMCs were 
isolated on the indicated days after trans-
plantation, and the frequency of T cells se-
creting IL-2 or IFN- in response to donor 
islets was determined by ELISPOT assay. Re-
sults are presented as numbers of cytokine-
producing cells per 2.5 × 105 PBMCs in each 
triplicate culture. R, responder cells only; 
R+S, responder cells stimulated with porcine 
islet cells; (), negative control responder 
cells from unsensitized monkeys stimulated 
with porcine islet cells; (+), positive control 
responder cells from sensitized monkeys 
stimulated with porcine islet cells. Error bars 
indicate SE. (C) Anti-Gal IgG levels were 
measured at the indicated time before and 
after porcine islet transplantation via ELISA.2484 Inducing T cell tolerance in situ | Jung et al.
diseases (Aichele et al., 1994; Hawiger et al., 2001; Fu and   
Jiang, 2010). Because of their pivotal role in controlling tol-
erance responses, DCs have emerged as strong candidates 
for modulating the immune system in an antigen-specific 
manner and as targets for immunotherapy for diverse conditions 
(Tarner et al., 2003; van Duivenvoorde et al., 2006; Steinman 
and Banchereau, 2007; Tarbell et al., 2007; Zahorchak et al., 
2007). Numerous strategies have been devised to generate stable 
tolerogenic DCs, including their modification with chemicals 
(Buckland and Lombardi, 2009), cytokines (Torres-Aguilar 
et al., 2010), peptides (Delgado, 2009), and immunosuppres-
sive drugs (Turnquist et al., 2007), as well as gene modifi-
cation (Tan et al., 2005). Most of these strategies have 
focused on the maturation of DCs in vitro under specific 
culture  conditions  and  the  subsequent  i.v.  injection  of 
tolerogenic DCs to induce T cell tolerance. This method for   
inducing tolerogenic DCs in vitro shows fairly good effects in 
some cases (Tarbell et al., 2007; Zahorchak et al., 2007). How-
ever, it would be preferable if we could induce tolerance 
control and MD-3–treated cells. In addition, inhibitory sig-
naling through the interaction of PD1 and PD-L1/L2 and 
CTLA-4 and B6 appears not to play a major role in our 
system, as the expression levels of PD-L1, PD-L2, and CTLA-4 
were not higher in MD-3–treated DCs, as compared with 
control (Fig. 5 A).
In in vitro experiments, MD-3 treatment resulted in the 
generation of semimature DCs. A similar response was ob-
served in vivo after the sequential injection of MD-3 and 
LPS. To determine whether the in vivo induction of T cell 
tolerance was mediated primarily by DCs, we developed a 
mouse model system in which DCs were almost completely 
ablated by i.v. injection of saporin-conjugated anti-CD11c 
IT. Tolerance induction did not occur in this system. These 
data clearly indicate that MD-3–induced tolerance was medi-
ated by DCs.
There is increasing evidence that DCs are charged with 
maintaining tolerance to self or innocuous antigens, the fail-
ure of which can lead to autoimmune and/or inflammatory 
Figure 8.  Achievement of long-term survival of a porcine islet xenograft in a nonhuman primate via combination therapy including MD-3. 
(A) After successfully inducing type 1 diabetes in Rhesus monkey via STZ administration, hyperglycemia was controlled by s.c. injecting human recombi-
nant insulin (Exotic insulin). Adult porcine islets (100,000 IEQs/kg) were intraportally transplanted into Rhesus monkeys (R052 and R049) that received 
MD-3 combined with rapamycin and anti-CD154 antibody. Blood glucose level and serum porcine C-peptide concentration were measured at the indi-
cated time after porcine islet transplantation. (B) PBMCs were isolated at 127 and 7 d after transplantation from R052 and R049, respectively, and the 
frequency of T cells secreting IL-2 or IFN- in response to donor islets (I) or allogeneic PBMCs (A) was determined by ELISPOT assay. Results are presented 
as numbers of cytokine-producing cells per 5 × 105 PBMCs in each triplicate culture. R, responder cells only; R+I, responder cells stimulated with porcine 
islet cells; R+A, responder cells stimulated with allogeneic PBMCs; (), unsensitized monkeys as a negative control; (+), sensitized monkeys as a positive 
control. Error bars indicate SE. (C) Anti-Gal IgG levels were measured at the indicated time before and after porcine islet transplantation via ELISA.JEM Vol. 208, No. 12 
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specific pathogen-free facility. Mice and pigs were maintained under specific 
pathogen-free conditions at the animal facility of the Center for Animal Re-
source Development, SNU College of Medicine. Experiments were per-
formed after receiving approval from the Institutional Review Board of 
SNU College of Medicine and the Institutional Animal Care and Use Com-
mittee of the Institute of Laboratory Animal Resources, SNU. Islet recipi-
ents were Rhesus macaques (Macaca mulatta) maintained at the SNU Hospital 
Non-human Primate Center. The age of the recipients ranged from 48 to   
60 mo, and their weight ranged from 4.5 to 5.5 kg. This study was conducted 
as approved by the SNU Hospital Animal Care and Use Committee and   
according to the National Institutes of Health guidelines.
Development  of  anti–human  ICAM-1  monoclonal  antibody  and 
mapping of its binding domain. A hybridoma cell line producing the 
MD-3  monoclonal  antibody  was  generated  by  fusing  splenocytes  from 
BALB/c mice immunized with human ICAM-1/Fc fusion proteins and 
SP2/0-Ag14 myeloma cells. To identify the ICAM1 domain for MD-3 anti-
body  binding,  human  and  mouse  ICAM1  genes  were  obtained  from   
N. Hogg (Cancer Research UK, London, England, UK). The monkey ICAM-1 
gene was cloned based on the published sequence (available from GenBank/
EMBL/DDBJ under accession no. NM_001047135.1). The chimeric con-
structs were cloned according to a previously described protocol (Berendt   
et al., 1992). HEK293 cells transfected with plasmid DNA were stained 
with primary antibody at 4°C for 30 min. After washing in PBS with 0.05% 
Tween 20 and staining with FITC-conjugated anti–mouse Ig antibody at 
4°C for 30 min, the live cells, gated as the propidium iodide (Sigma-Aldrich)–
negative population, were analyzed using FACSCalibur (BD) equipped with 
CellQuest Pro software (BD).
Generation  of  monocyte-derived  DCs.  Human  CD14+  monocytes 
were isolated from healthy volunteers using magnetic sorting, and immature 
DCs were derived from purified monocytes by culture with 1,000 U/ml 
GM-CSF (PeproTech) and 1,000 U/ml IL-4 (PeproTech) in the absence or 
presence of 10 µg/ml of antibodies, as described previously (Subklewe   
et al., 1999), and were matured on day 6 by adding 5 µg/ml LPS (Sigma- 
Aldrich) after washing. The next day, the cells were harvested for flow   
cytometry, and the cytokine concentration in the culture supernatant was 
measured by Cytometric Bead Array (BD). The following fluorochrome-
labeled monoclonal antibodies were purchased from BD or Dinona: anti–
human MHC class I (YG13), MHC class II (L243), CD11c (B-ly6), CD80 
(L307.4), C86 (FUN-1), CD40 (5C3), PD-L1 (MIH1), PD-L2 (MIH18), 
and CTLA-4 (BNI3).
Generation  of  humanized  mice.  Humanized  mice  were  generated   
according to a previously described protocol (Ito et al., 2002). NOG mice 
were exposed to 200 rad of total body irradiation from a 137Cs source. The 
next day, each recipient mouse received 1–2 × 105 CD34+ cells that were 
purified from human cord blood cells using magnetic sorting (Miltenyi Bio-
tec). Repopulation of total human hematopoietic cells and T cells in periph-
eral blood was monitored weekly by flow cytometry after staining with 
anti–human MHC class I and CD3 antibodies. At the time of sacrifice, 
spleens were collected, and single cells were resuspended in flow cytometry 
buffer (PBS with 0.1% bovine serum albumin and 0.1% Na azide). After 
staining with fluorochrome-conjugated antibodies for 30 min at 4°C, the 
live  cells  were  analyzed  using  a  flow  cytometer.  The  following  fluoro-
chrome-labeled monoclonal antibodies were purchased from BD or Dinona: 
anti–human MHC class I (YG13), CD3 (UCHT1), CD4 (RPA-T4), CD8 
(DN17), CD11c (B-ly6), CD14 (MEM-18), CD15 (HI98), CD19 (HIB19), 
CD80 (L307.4), C86 (FUN-1), and CD123 (9F5).
Porcine pancreas procurement and islet isolation. A total pancreatec-
tomy was performed without warm ischemia time, and islet isolation was 
performed using the modified Ricordi method, as previously described (Jin 
et al., 2010). In brief, Liberase MTF C/T (Roche) or CIzyme collagenase 
MA and CIzyme BP protease (VitaCyte) were dissolved in endotoxin-free 
status in an in vivo system without the need for in vitro ma-
nipulation of DCs (Morelli and Thomson, 2007). In this re-
spect, a major advantage of using MD-3 is that, as we have 
shown, in vivo challenge with this antibody resulted in the in 
situ generation of semimature DCs and subsequent induction 
of antigen-specific T cell tolerance.
Because it is important to evaluate the effects of MD-3 
under conditions that more closely mimic human physiol-
ogy, we tested whether MD-3 was also able to induce T cell 
tolerance in Rhesus macaques. Porcine pancreatic islets were 
transplanted intraportally into monkeys that had been admin-
istered MD-3 three times before transplantation. Although 
MD-3 alone cannot achieve long-term graft survival, it effi-
ciently induced T cell tolerance against porcine islet antigens 
as shown by ELISPOT analysis. We speculated that the re-
jection would be mediated by antibodies against thymus- 
independent carbohydrate antigen as the monkeys exhibited 
early rapid rising of anti-Gal IgG levels (Fig. 7 C). A previous 
study reported that rapidly induced T cell–independent xeno-
antibody production is mediated by marginal zone B cells 
and requires help from NK cells via the CD40–CD40L inter-
action (Li et al., 2007). By using MD-3 with a combination 
of anti-CD154 antibody and rapamycin, which is known to 
inhibit NK-mediated cytotoxicity, we were able to achieve 
porcine islet graft survival for >140 d by now. In addition, in 
these recipients, we observed no increases in Gal-specific IgG 
antibody levels after transplant (Fig. 8 C).
In this study, we demonstrated that MD-3 treatment in-
duced antigen-specific T cell tolerance against grafted antigens 
rather than generalized immunosuppression. The present data 
raise the possibility that the administration of MD-3 may also 
be able to induce T cell tolerance to all types of antigens within 
the recipients, including latent viruses such as Epstein-Barr 
virus. This possibility should be considered in a clinical trial. 
However, during latency, viral genes are incorporated into 
the host chromosome, and viral antigens are not able to be   
efficiently presented to T cells. Therefore, host T cells appear 
not to be tolerized to these viral antigens during this latent 
stage, during the time recipients are treated with MD-3.
The mechanism of how ICAM-1 signaling can handle 
DCs for their maturation has never been shown before. This 
work is now under way in this laboratory.
In summary, we were able to induce in situ antigen- 
specific T cell tolerance in an in vivo system. MD-3, a unique 
monoclonal antibody that recognizes domain 2 of human 
ICAM-1, efficiently induced the differentiation of immature 
DCs into semimature DCs both in vitro and in vivo. This in-
duction of T cell tolerance is particularly meaningful because 
it was highly specific for target antigens. Therefore, MD-3–
induced tolerance is a highly promising strategy for the pre-
vention of transplant rejection.
MATERIALS AND METHODS
Animals. NOG mice were obtained from the Central Institute for Experi-
mental Animals (Kawasaki, Japan). The donor pigs, Seoul National Univer-
sity (SNU) miniature pigs (Kim et al., 2009), were bred in a barrier-sustained 2486 Inducing T cell tolerance in situ | Jung et al.
exposed to infuse the islets. A 24- or 22-gauge catheter was inserted through 
the jejunal vein and approached near the portal vein. The porcine islets were 
infused with gravity pressure for 8–12 min. After infusion, the vessel was li-
gated with a 5-0 Prolene suture. Finally, the abdominal cavity was closed   
using a common method. After surgery, the tether system was applied for 
continuous fluid therapy and infusion of low dose sugar, if necessary.
ELISPOT  assay. The frequencies of IL-2– or IFN-–secreting antigen- 
specific T cells in spleens of humanized mice and peripheral blood of 
nonhuman primates were measured using an ELISPOT kit (Mabtech). Anti–IL-2   
or IFN- capture antibody-coated plates were washed four times with sterile 
PBS (200 µl/well) and blocked for 30 min with 10% human serum–supplemented 
RPMI 1640 media at room temperature. After removing the media, 3 × 105 
splenocytes from the humanized mice or 2.5 × 105 of PBMCs from 
nonhuman primates were cultured with 5 × 104 porcine islet cells in RPMI 
1640 media supplemented with 10% human serum for 40 h at 37°C in a 5% 
CO2 incubator. For humanized mice, 0.1 mg/ml KLH or T cell–depleted   
-irradiated 7 × 105 human PBMCs pooled from three volunteers were also 
used as stimulators. After the 40-h culture, cells were removed, and the plates   
were washed five times with PBS (200 µl/well). Alkaline phosphatase–conju-
gated detecting antibody diluted at 1:200 or 1:1,000 for IL-2 or IFN-, re-
spectively, in 100 µl PBS containing 0.5% fetal bovine serum was then added 
and incubated for 2 h at room temperature. The plates were washed five times 
with PBS, and 100 µl BCIP/NBP substrate was added. Color development 
was stopped by washing with tap water. The resulting spots were counted on 
a computer-assisted ELISPOT Reader System (AID).
Generation of anti-CD11c IT. To produce the anti–human CD11c anti-
body–saporin IT, saporin was purchased from Sigma-Aldrich, and saporin 
conjugation of antibody was performed as described previously with some 
modifications (McGraw et al., 1994). In brief, anti–human CD11c antibody 
was activated with N-succinimidyl-3-(2-pyridyldithio)-propionate, conju-
gated with thiolated saporin, and added to N-ethylmaleimide to block unre-
acted sulfhydryl groups. After removing the unconjugated saporin by protein 
G affinity chromatography, the anti-CD11c–saporin complexes were eluted 
with ImmunoPure elution buffer (Thermo Fisher Scientific) and dialyzed 
against PBS. The possibility of contamination by free saporin was ruled out 
by SDS-PAGE.
Cell adhesion assay. The IB4 monoclonal antibody (anti-CD18) has been 
previously described (Wright et al., 1983), as has the monoclonal anti-
body R6-5-D6 against ICAM-1 (Smith et al., 1988; Berendt et al., 1992). 
HUVECs were prepared and cultured on hydrated collagen gels (for mono-
cyte adhesion) or directly on fibronectin-coated 96-well plates (for neutro-
phil adhesion), as described previously (Muller et al., 1989). For neutrophil 
adhesion, HUVEC monolayers were activated by culturing them in 10 ng/ml 
TNF overnight. HUVECs were not activated for monocyte adhesion assays. 
Under these conditions, when freshly isolated PBMCs are added, lympho-
cytes do not stick to the endothelial cells, but monocytes do (Muller and 
Weigl, 1992). Neutrophils (Lou et al., 2007) and PBMCs (Muller and Weigl, 
1992) were isolated as described previously and subjected to adhesion assays 
using the standard approaches (Muller and Weigl, 1992; Lou et al., 2007; 
Muller and Luscinskas, 2008). In brief, freshly isolated polymorphonuclear 
neutrophils or PBMCs were resuspended to 1 × 106 cells/ml or 2 × 106 
cells/ml, respectively, mixed gently with monoclonal antibodies at a final 
concentration of 20 µg/ml, and added to the endothelial monolayers for 
25 min at 37°C. Monolayers were washed free of nonadherent cells, fixed, 
and stained with Wright-Giemsa stain for microscopic evaluation. Six repli-
cates of each variable were performed for each experiment.
Histopathological examination and immunohistochemical staining 
of tissue sections. Formalin-fixed, paraffin-embedded tissues were sec-
tioned to a thickness of 4 µm and stained with hematoxylin and eosin (H&E). 
For immunohistochemistry, formalin-fixed, paraffin-embedded tissue sec-
tions were dewaxed in xylene, rehydrated using a graded alcohol series, and 
water and diluted to a total volume of 1 ml/g of pancreas weight with a 
preservation solution at 4°C and intraductally administered. The preserva-
tion solution was composed of Na hydroxide, potassium hydroxide, calcium 
chloride, magnesium sulfate, Na phosphate, d-mannitol, and NaCl. During 
digestion, the pancreas, which was inflated with collagenase, was incubated 
without shaking for 12–15 min at 35–37°C until the pancreas tissue was 
loosened. This was followed by manual shaking with serial sampling. After 
free islets were observed in the serial sample, digestion was stopped by cool-
ing to 4°C and exposing the islets to 10% porcine serum. Islets were purified 
with a continuous OptiPrep density gradient (Axis-Shield) and a Cobe 2991 
cell separator (Gambro BCT Inc.). Purified islets were cultured overnight in 
Medium 199 (Invitrogen) supplemented with 10% porcine serum, 10 mM 
nicotinamide (Sigma-Aldrich), and 1% penicillin-streptomycin at 37°C.
Porcine islet grafts in humanized mice. Diabetes was induced by high-
dose i.v. STZ (total of 200 mg/kg, split into two doses separated by 24 h), 
and mice with fasting glucose levels >250 mg/dl were considered diabetic. 7 d 
later, isolated porcine islets (5,000 IEQs/mouse) were transplanted under the 
kidney capsule. Peripheral blood was sampled weekly from the retroorbital 
sinus to monitor blood glucose levels using a portable glucometer (Accu-
Chek; Roche), and porcine C-peptide levels in serum were determined by 
radioimmunoassay (Linco) according to the manufacturer’s protocol. A suc-
cessful engraft was defined as porcine C-peptide >0.5 ng/ml, and graft   
rejection was defined as the day of C-peptide <0.1 ng/ml. Rejection was 
confirmed by histological analysis of the grafts.
Induction of type 1 diabetes in nonhuman primates. A central venous 
catheter (5Fr. Dual-Lumen PICC; Bard Access System) was inserted into the 
right internal jugular vein in monkeys under general anesthesia. Monkeys 
were fasted overnight and were prehydrated with normal saline (0.9% NaCl, 
40–60 ml/kg/day i.v.) via a tether system for 12 h before STZ (USB Co.) 
administration to reduce adverse nephrotoxic effects. Butorphanol or meto-
clopramide was also administered to prevent chemically induced vomiting 
caused by the STZ. A high dose of STZ (110–120 mg/kg) was diluted with 
10 ml normal saline and given i.v. within 5 min. Additional hydration with 
normal saline was given for 2–4 h. Blood glucose levels were measured using 
a portable glucometer (Accu-Chek) or a continuous glucose monitoring sys-
tem (Guardian RT; Medtronic Inc.). STZ was administered in the morning, 
and a light meal was given to the monkeys in the afternoon. If there was a 
loss of appetite, dextrose was infused via a tether system to prevent hypogly-
cemia. Liver and kidney function tests were performed before and after STZ 
administration, and C-peptide levels were assessed by radioimmunoassay 
(Linco) according to the manufacturer’s protocol. After successfully inducing 
type 1 diabetes, blood glucose levels were checked at least two or three times 
per day, and hyperglycemia was controlled by s.c. injecting human recombi-
nant insulin such as Humalog (Eli Lilly), Novolin N (Green cross), or Lantus 
(Sanofi-Aventis). Fasting and nonfasting blood glucose levels were main-
tained in the diabetic monkeys at approximately <150 mg/dl (>8.3 mmol/l) 
and <200 mg/dl (11.1 mmol/l), respectively. Complete type 1 diabetes was 
confirmed by persistent hyperglycemia and <0.2 ng/ml of C-peptide levels 
based on the i.v. glucose tolerance test. In brief, after an overnight fast and 
no insulin, 0.5 g/kg of 50% dextrose solution added to same volume of nor-
mal saline was infused i.v. for 1 min. Blood glucose levels were measured in 
monkeys before and 2, 5, 15, 30, 60, 90, and 120 min after infusion. Insulin 
and C-peptide levels were measured at the same time intervals.
Islet  transplantation  into  nonhuman  primates.  All  monkeys  were 
fasted for 12 h before surgery. After premedicating the monkeys with atro-
pine sulfate (0.04 mg/kg s.c.; Huons), general anesthesia was induced with 
thiopental Na (25 mg/kg i.v.; JWP) and maintained with 1% isoflurane, 
N2O, and O2. Lactated Ringer’s solution or 5% dextrose saline was adminis-
tered i.v. during the operation. Cefazolin Na (25 mg/kg i.v.; Chong Kun Dang) 
was given prophylactically, and meloxicam (0.2 mg/kg i.v.; Boehringer   
Ingelheim)  was  administered  for  antiinflammatory  and  analgesic  effects   
before surgery. A laparotomy was performed, and the jejunal arch was JEM Vol. 208, No. 12 
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incubated in an endogenous peroxide-blocking solution for 5 min. Antigen 
retrieval was performed by incubating the sections in 6 mM of citrate buf-
fer at 99°C for 20 min using the Bond Max system (Leica), and nonspecific 
staining was prevented by treating the tissue sections with rabbit serum   
(1% in PBS) for 30 min. Anti–human insulin (Dako), CD3 (F7.2.38; Dako),   
and CD68 (PG-M1; Dako) antibodies were applied for 30 min, and anti-
body binding was detected using a VECTASTAIN Elite ABC kit (PK6101; 
Vector Laboratories). Microscopic observations were performed with an 
ECLIPSE  80i  Bright-Field  Microscope  Set  (Nikon)  equipped  with  CFI 
10×/22 eyepiece, Plan Fluor objectives (with 4×, 10×, 20×, and 100× ob-
jectives)  and  DS-Fi1  camera.  We  used  NIS-Elements  BR  3.1  software 
(Nikon) for image acquisition.
Statistical analysis. All data were analyzed using Prism software (GraphPad 
Software). Data are presented as mean ± SE. Comparison between groups 
was performed by either Student’s t test (two groups) or one-way analysis of 
variance (multiple groups). Survival data were analyzed by log-rank test.   
P-values <0.05 were considered significant.
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